Correspondence 0001104659-23-101199 from Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635) (RNAZ)
Transcode Therapeutics, Inc. (RNAZ) (CIK 0001829635)
Date: Sept. 15, 2023 · CIK: 0001829635 · Accession: 0001104659-23-101199
AI Filing Summary & Sentiment
File numbers found in text: 333-274251
Letter
VIA EDGAR Division of Corporation Finance Office of Life Sciences Attention: Tim Buchmiller Re: TransCode Therapeutics, Inc. Acceleration Request for Registration Statement on Form S-1, as amended File No. 333-274251
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), TransCode Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 19, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Finn Murphy at (212) 459-7257.
Please contact Michael Bison and Finnbarr Murphy of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com), respectively, with any questions.
Sincerely,
TRANSCODE THERAPEUTICS,
INC.
Show Raw Text
CORRESP
1
filename1.htm
September 15, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, NE
Washington, DC 20549-3233
Attention: Tim Buchmiller
Re: TransCode Therapeutics, Inc.
Acceleration Request for Registration Statement
on Form S-1, as amended
File No. 333-274251
Dear Mr. Buchmiller:
Pursuant to Rule 461 under the Securities Act of
1933, as amended (the “Act”), TransCode Therapeutics, Inc. (the “Company”) hereby requests that
the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to
September 19, 2023, at 5:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter
LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request,
the Company acknowledges that it is aware of its responsibilities under the Act.
Once
the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Finn Murphy
at (212) 459-7257.
Please contact Michael Bison and Finnbarr Murphy
of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com),
respectively, with any questions.
Sincerely,
TRANSCODE THERAPEUTICS,
INC.
/s/
Robert Michael Dudley
Robert
Michael Dudley
Chief
Executive Officer
cc:
Thomas A. Fitzgerald, TransCode Therapeutics, Inc.
Michael Bison, Goodwin Procter LLP
Finn Murphy, Goodwin Procter LLP